Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Classical hematology 1

Conditions

Venous Thromboembolism 1Multiple Myeloma 1

Interventions

Dexamethasone 16daratumumab 14Bortezomib 11Lenalidomide 9pomalidomide 7Calcium Dobesilate 6isatuximab 4belantamab mafodotin 4Cyclophosphamide 4carfilzomib 3Melphalan 3tocilizumab 2iberdomide 2dexamethasone acetate 2dexamethasone 21-phosphate 2auricularum 2Specimen Handling 2Maintenance 2Injections 2Immunotherapy, Adoptive 2Exercise Therapy 2Drug Therapy 2CT103A chimeric antigen receptor 2Biopsy 2zanubrutinib 1trametinib 1talquetamab 1selinexor 1pembrolizumab 1ixazomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Multiple Myeloma × Rivaroxaban × Clear all
NCT06580223 2025-07-18

Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 3 Not yet recruiting
530 enrolled
Classical hematologyPlasma cell

Multiple Myeloma, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡